Mann M, Krishnan S, Vadlamudi R K
Department Obstetrics and Gynecology, UT Health Science Center, San Antonio, TX, USA.
Minerva Ginecol. 2012 Feb;64(1):75-88.
Estrogen receptor (ERα) plays an important role in the initiation and progression of breast cancer. Many breast cancer patients respond positively to hormonal therapy; however, initial or acquired resistance to endocrine therapies frequently occurs and tumors recur as metastases. Emerging evidence suggests that ERα action is complex and involves functional interactions with coregulators. The levels of ERα coregulator proteins are tightly regulated under normal conditions and ERα-coregulator proteins have the potential to be differentially expressed in malignant tumors and have altered functions leading to tumor progression and metastases. In this review, we summarize recent findings that relate to ERα coregulators and discuss implications of ERα coregulator deregulation in breast cancer metastasis.
雌激素受体(ERα)在乳腺癌的发生和发展中起着重要作用。许多乳腺癌患者对激素治疗反应良好;然而,内分泌治疗的初始或获得性耐药经常发生,肿瘤会复发并转移。新出现的证据表明,ERα的作用很复杂,涉及与共调节因子的功能相互作用。在正常情况下,ERα共调节因子蛋白的水平受到严格调控,并且ERα共调节因子蛋白在恶性肿瘤中可能存在差异表达,其功能改变会导致肿瘤进展和转移。在本综述中,我们总结了与ERα共调节因子相关的最新研究结果,并讨论了ERα共调节因子失调在乳腺癌转移中的意义。